RxDoctor Payments Data

Hugo Riffel-Dalinger, MD

Cardiovascular Disease · Glendale, CANPI 1699727990

Payments from drug & device makers

$69,849in general payments, 2019–2025

Across 827 payments — averaging $84.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$22K
  • Johnson & Johnson$21K
  • Amgen$11K
  • Boehringer Ingelheim$2K
  • Novartis$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $10K from 35 others

What the payments were for

  • Speaking & faculty fees$45,05465%
  • Travel & lodging$4,6477%
  • Food & beverage$20,05529%
  • Education$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,849 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$549,813
Medicare patients
440
Services billed
4,054

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat30$335,240
EntrestoSacubitril/Valsartan155$179,936
XareltoRivaroxaban194$167,937
OpsumitMacitentan13$164,057
EliquisApixaban147$125,917
JardianceEmpagliflozin92$79,331
Repatha SureclickEvolocumab56$48,735
VerquvoVericiguat41$47,796
JanuviaSitagliptin Phosphate29$36,747
FarxigaDapagliflozin Propanediol38$33,099
Repatha PushtronexEvolocumab28$22,099
MultaqDronedarone Hcl28$19,290
NexlizetBempedoic Acid/Ezetimibe37$17,873
VascepaIcosapent Ethyl31$10,577
LinzessLinaclotide11$6,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerAdempas$646$335,24030 claims
NovartisEntresto$1,937$179,936155 claims
Johnson & JohnsonXarelto$21,011$167,937194 claims
Actelion Pharmaceuticals US, Inc.Opsumit$1,099$164,05713 claims
PfizerEliquis$400$125,917147 claims
MerckVerquvo, Januvia$22,296$84,54370 claims
Boehringer IngelheimJardiance$2,419$79,33192 claims
AstraZenecaFarxiga$1,153$33,09938 claims
Sanofi-aventis U.S. LLCMultaq$71$19,29028 claims
Esperion Therapeutics, Inc.Nexlizet$1,021$17,87337 claims
Kowa Pharmaceuticals America, Inc.Bystolic$249$2,05612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →